RU97120726A - HIGH DOSES OF CHROME TRIPIKOLINATE FOR TREATMENT OF SECOND TYPE DIABETES - Google Patents

HIGH DOSES OF CHROME TRIPIKOLINATE FOR TREATMENT OF SECOND TYPE DIABETES

Info

Publication number
RU97120726A
RU97120726A RU97120726/14A RU97120726A RU97120726A RU 97120726 A RU97120726 A RU 97120726A RU 97120726/14 A RU97120726/14 A RU 97120726/14A RU 97120726 A RU97120726 A RU 97120726A RU 97120726 A RU97120726 A RU 97120726A
Authority
RU
Russia
Prior art keywords
chromium
tripicolinate
chromic
synthetic
treatment
Prior art date
Application number
RU97120726/14A
Other languages
Russian (ru)
Other versions
RU2195934C2 (en
Inventor
Марк Мккарти
Original Assignee
Ньютришн 21
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/440,362 external-priority patent/US6329361B1/en
Application filed by Ньютришн 21 filed Critical Ньютришн 21
Publication of RU97120726A publication Critical patent/RU97120726A/en
Application granted granted Critical
Publication of RU2195934C2 publication Critical patent/RU2195934C2/en

Links

Claims (15)

1. Способ снижения гипергликемии и стабилизации уровня глюкозы в крови человека, заключающийся в том, что человеку, нуждающемуся в этом, ежедневно вводят 1000 - 10000 мкг хрома в виде синтетического трипиколината хрома.1. A method of reducing hyperglycemia and stabilizing the level of glucose in a person’s blood, which consists in injecting 1,000 to 10,000 micrograms of chromium in the form of synthetic chromic tripicolinate daily to a person in need. 2. Способ по п. 1, заключающийся в том, что ежедневно вводят 1000 - 5000 мкг хрома в виде синтетического трипиколината хрома. 2. The method according to p. 1, which consists in the fact that daily enter 1000 - 5000 μg of chromium in the form of synthetic chromic tripicolinate. 3. Способ по п. 1, отличающийся тем, что указанный трипиколинат хрома находится в фармацевтически приемлемом носителе. 3. The method according to p. 1, characterized in that the said chromic tripicolinate is in a pharmaceutically acceptable carrier. 4. Способ по п. 3, отличающийся тем, что указанный трипиколинат хрома вводится орально. 4. The method according to p. 3, characterized in that the said chromic tripicolinate is administered orally. 5. Способ по п. 3, отличающийся тем, что указанный трипиколинат хрома вводится парентерально. 5. The method according to p. 3, characterized in that said chromium tripicolinate is administered parenterally. 6. Синтетический трипиколинат хрома в единичной дозировочной форме, каждая доза при этом составляет 100 - 10000 мкг, применяемый для лечения гипергликемии и/или стабилизации уровня глюкозы в крови у лиц, нуждающихся в этом. 6. Synthetic chromium tripicolinate in a single dosage form, each dose being 100 - 10,000 μg, used to treat hyperglycemia and / or stabilize blood glucose in people who need it. 7. Трипиколинат хрома по п. 6, отличающийся тем, что каждая доза содержит 1000 - 5000 мкг хрома. 7. Chromium tripicolinate according to claim 6, characterized in that each dose contains 1000-5000 μg of chromium. 8. Трипиколинат хрома по п. 6 или 7, отличающийся тем, что он находится в форме, пригодной для орального введения. 8. Chromium tripicolinate according to claim 6 or 7, characterized in that it is in a form suitable for oral administration. 9. Трипиколинат хрома по п. 6 или 7, отличающийся тем, что он находится в форме, пригодной для парентерального введения. 9. Chromium tripicolinate according to claim 6 or 7, characterized in that it is in a form suitable for parenteral administration. 10. Трипиколинат хрома по п. 6 или 7, отличающийся тем, что он находится в фармацевтически приемлемом носителе. 10. Chromium tripicolinate according to claim 6 or 7, characterized in that it is in a pharmaceutically acceptable carrier. 11. Применение синтетического трипиколината хрома в единичной дозировочной форме, причем каждая доза содержит 1000 - 10000 мкг хрома, для получения лекарственного средства для лечения гипергликемии и/или стабилизации уровня глюкозы в крови у лиц, нуждающихся в этом. 11. The use of synthetic chromic tripicolinate in a single dosage form, each dose containing 1000-10,000 micrograms of chromium, for the preparation of a medicament for the treatment of hyperglycemia and / or stabilization of blood glucose levels in persons in need thereof. 12. Применение по п. 11, отличающееся тем, что каждая доза содержит 1000 - 5000 мкг хрома. 12. The use according to claim 11, characterized in that each dose contains 1000 to 5000 micrograms of chromium. 13. Применение по п. 11 или 12, отличающееся тем, что указанный трипиколинат хрома находится в форме, пригодной для орального введения. 13. The use according to claim 11 or 12, characterized in that said chromium tripicolinate is in a form suitable for oral administration. 14. Применение по п. 11 или 12, отличающееся тем, что указанный трипиколинат хрома находится в форме, пригодной для парентерального введения. 14. The use according to claim 11 or 12, characterized in that said chromium tripicolinate is in a form suitable for parenteral administration. 15. Применение по п. 11 или 12, отличающееся тем. что указанный трипиколинат хрома находится в фармацевтически приемлемом носителе. 15. The application of claim 11 or 12, characterized in that. that said chromium tripicolinate is in a pharmaceutically acceptable carrier.
RU97120726/14A 1995-05-12 1996-05-08 High doses of chrome tripicolinate for treatment of non-insulin dependent diabetes mellitus (type ii) RU2195934C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/440,362 1995-05-12
US08/440,362 US6329361B1 (en) 1995-05-12 1995-05-12 High-dose chromic picolinate treatment of type II diabetes

Publications (2)

Publication Number Publication Date
RU97120726A true RU97120726A (en) 1999-09-27
RU2195934C2 RU2195934C2 (en) 2003-01-10

Family

ID=23748461

Family Applications (1)

Application Number Title Priority Date Filing Date
RU97120726/14A RU2195934C2 (en) 1995-05-12 1996-05-08 High doses of chrome tripicolinate for treatment of non-insulin dependent diabetes mellitus (type ii)

Country Status (15)

Country Link
US (1) US6329361B1 (en)
EP (1) EP0825861B1 (en)
JP (1) JP3699124B2 (en)
AR (1) AR004486A1 (en)
AT (1) ATE227127T1 (en)
AU (1) AU5733796A (en)
BR (1) BR9608835A (en)
DE (1) DE69624699T2 (en)
DK (1) DK0825861T3 (en)
ES (1) ES2183952T3 (en)
IL (1) IL118222A (en)
PT (1) PT825861E (en)
RU (1) RU2195934C2 (en)
WO (1) WO1996035421A1 (en)
ZA (1) ZA963735B (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962030A (en) 1997-03-07 1999-10-05 Akesis Pharmaceuticals, Inc. Dietary supplement and method of treatment for diabetic control
US5789401A (en) * 1997-08-08 1998-08-04 Nutrition 21 High-dose chromium/biotin treatment of type II diabetes
AU751431B2 (en) * 1997-08-08 2002-08-15 Nutrition 21 Chromium/biotin treatment of type II diabetes
EP0925790A1 (en) * 1997-12-17 1999-06-30 Kartar Dr. Lalvani Vitamin and mineral combinations for the treatment of syndrome X and non-insulin dependent diabetes (NIDDM)
US5932258A (en) * 1998-04-06 1999-08-03 The Iams Company Composition and process for improving glucose metabolism in companion animals
US5948772A (en) 1998-08-28 1999-09-07 Ambi Inc. Chromium picolinate compositions and uses thereof
US6143301A (en) * 1998-08-28 2000-11-07 Ambi Inc. Chromium picolinate compositions and uses thereof
US5905075A (en) * 1998-08-28 1999-05-18 Ambi Inc. Chromium nicotinate compositions and uses thereof
US6852760B1 (en) 1998-09-17 2005-02-08 Akesis Pharmaceuticals, Inc. Compositions and methods for treatment for glucose metabolism disorders
US6376549B1 (en) 1998-09-17 2002-04-23 Akesis Pharmaceuticals, Inc. Metforimin-containing compositions for the treatment of diabetes
CN1665566A (en) 2000-09-21 2005-09-07 营养21公司 Methods and compositions for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity, reduction of hyperglycemia, and reduction of hypercholesterolemia with chromium c
AU2003226313A1 (en) * 2002-04-23 2003-11-10 Nutrition 21, Inc. Chromium compositions and methods for using the same for inhibiting drug-induced insulin resistance
CN100457122C (en) * 2002-05-14 2009-02-04 尼普洛株式会社 Medicine for prevention of and treatment for amyloidosis
US6831077B2 (en) * 2002-07-25 2004-12-14 Comprehensive Neuroscience, Inc. Augmentation of atypical antipsychotic agent pharmacotherapy with chromium supplementation
US20050019435A1 (en) * 2003-07-21 2005-01-27 Jeffrey Young Method of treating non-insulin dependent diabetes mellitus and related complications
US20050085454A1 (en) * 2003-10-16 2005-04-21 Natreon Inc. Phenolic antioxidant-chromium complexes for treatment or prevention of type 2 diabetes or glucose intolerance
EP2120930A4 (en) * 2007-01-31 2012-12-05 Nutrition 21 Inc Use of chromium histidinate for treatment of cardiometabolic disorders
EP3050568B1 (en) 2007-03-13 2020-12-02 JDS Therapeutics, LLC Methods and compositions for the sustained release of chromium
WO2009002867A2 (en) 2007-06-26 2008-12-31 Nutrition 21, Inc. Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
EP3513790A1 (en) 2009-07-01 2019-07-24 JDS Therapeutics, LLC Chromium complexes as enhancers of brain glucose transporters
ES2927800T3 (en) 2011-03-01 2022-11-11 Nutrition 21 Llc Insulin and chromium composition for the treatment and prevention of diabetes, hypoglycemia and related disorders
CN107404902A (en) 2015-02-13 2017-11-28 马斯公司 Pet food feeds system
GB2564295A (en) 2016-02-11 2019-01-09 Nutrition 21 Llc Chromium containing compositions for improving health and fitness
US10820617B1 (en) 2018-03-29 2020-11-03 Government Of The United States, As Represented By The Secretary Of The Air Force All inclusive electrolytes, vitamins, and protein powder training supplement

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4315927A (en) * 1980-08-08 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Dietary supplementation with essential metal picolinates
US5087623A (en) * 1988-05-31 1992-02-11 Nitrition 21 Chromic picolinate treatment
US5164384A (en) 1991-06-19 1992-11-17 Metagenics, Inc. Anabolic mineral formula

Similar Documents

Publication Publication Date Title
RU97120726A (en) HIGH DOSES OF CHROME TRIPIKOLINATE FOR TREATMENT OF SECOND TYPE DIABETES
ABERNETHY et al. Verapamil pharmacodynamics and disposition in young and elderly hypertensive patients: altered electrocardiographic and hypotensive responses
Roseman Dilantin toxicity: a clinical and electroencephalographic study
Aizenberg et al. Painful ejaculation associated with antidepressants in four patients.
EP1570823A3 (en) Substained analgesia achieved with buprenorphine
YU49083B (en) Process for obtaining pharmaceutical composition containing budesonide and formoterol
RU2002114820A (en) A method for treating diabetes
Jackson et al. Clinical trial of pyridoxine to reduce vincristine neurotoxicity
RO116771B1 (en) Method for preventing or treating the addiction on, tolerance or abuse of benzodiazepines
US5654334A (en) Analgesic use of N-L-α-aspartyl-L-phenylalanine 1-methyl ester
MY124465A (en) Reduction of infarct volume using citicoline
RU95113499A (en) METHOD FOR INCREASING URINITATION IN HUMAN, METHOD FOR REDUCING LEVELS OF CHOLESTEROL AND LOW DENSITY LIPOPROTEINS, APPLICATION OF (+) DOXAZOSINE
JP2947044B2 (en) Adjuvant therapy for immunodeficiency syndrome treatment
Latasch et al. Respiratory safety
EP0764025B1 (en) Method and medicine for alleviating jet lag
Gobeaux et al. Midazolam and flumazenil in ophthalmology
Bolte et al. Case of fluoxetine-induced remission of Raynaud's phenomenon—a case report
ATE247462T1 (en) USE OF METFORMIN FOR WEIGHT GAIN ASSOCIATED WITH VALPROATE AND OTHER PSYCHOTROPIC DRUGS
RU95112520A (en) APPLICATION 4'-IODO-4'-DEOXIDOXORUBICINE FOR THE TREATMENT OF AMYLOIDOSIS, METHOD OF TREATMENT OF AMYLOIDOSIS
Bibile et al. Pantothenol and the burning feet syndrome
Weksler et al. Lidocaine pretreatment effectively decreases the incidence of hiccups during methohexitone administration for dilatation and curettage
Thomas et al. A multidimensional comparison of nurse and patient controlled analgesia in the management of acute postsurgical pain.
Rappolt et al. Use of Inderal (propranolol-Ayerst) in Ia (early stimulative) and Ib (advanced stimulative) classification of cocaine and other sympathomimetic reactions
Ananth et al. Intramuscular lorazepam: A double-blind comparison with diazepam and placebo
ROTH et al. The effects of midazolam and temazepam on sleep and performance when administered in the middle of the night